CD94 and NKG2 are members of the NK cell receptor families, and are encoded in the natural killer gene complex (NKC) on human chromosome 12p12-13, one of the candidate chromosomal regions for rheumatic diseases. To examine a possible association between variations in CD94 and NKG2 genes and genetic susceptibility to rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), we carried out a systematic polymorphism screening of NKG2-A (KLRC1), NKG2-C (KLRC2) and CD94 (KLRD1) genes on a population basis. In NKG2-A, previously considered to be highly conserved, 10 polymorphisms in the noncoding region and introns, as well as one rare variation leading to an amino acid substitution within the transmembrane region, c.238T4A (Cys80Ser), were detected. In NKG2-C, in addition to the previously described two nonsynonymous substitutions, c.5G4A (Ser2Asn) and c.305C4T (Ser102Phe), two polymorphisms were newly detected in the noncoding region. In CD94, only one single nucleotide substitution was identified in the 5 0 untranslated region. When the patients and healthy individuals were genotyped for these variations, no significant association was observed. However, although statistically not significant, NKG2-A c.238T4A (Cys80Ser) was observed in three patients with RA, but in none of the healthy individuals and the patients with SLE. Unexpectedly, in the process of polymorphism screening, we identified homozygous deletion of NKG2-C in approximately 4.3% of healthy donors; under the assumption of Hardy-Weinberg equilibrium, the allele frequency of NKG2-C deletion was estimated to be 20.7%. These results demonstrated that, although human NKG2-A, -C and CD94 are generally conserved with respect to amino acid sequences, NKG2-A is polymorphic in the noncoding region, and that the number of genes encoded in the human NKC is variable among individuals, as previously shown for the leukocyte receptor complex (LRC), HLA and Fcg receptor (FCGR) regions.
Introduction
NK cells are lymphocytes that serve as components of the early, innate immune system. 1 NK cells can kill cellular targets such as tumor cells and infected cells, and also secrete cytokines that influence subsequent development of adaptive immunity. 2 Such functions of NK cells are regulated by the balance of signals via a multitude of activating and inhibitory NK cell receptors. 3, 4 The imbalance of the signals could lead to unregulated activation of both cytotoxicity and cytokine release by NK cells. Indeed, a role for NK cells has often been implicated in autoimmunity. 5 NKG2 and CD94 are members of C-type lectin-like NK cell receptors. 6, 7 NKG2-A, NKG2-C and NKG2-E form heterodimers with CD94 8, 9 and recognize the nonclassical MHC class I molecule, HLA-E, in humans. [10] [11] [12] NKG2-A/CD94 and NKG2-C, -E/CD94 transmit inhibitory and activation signals into NK cells, respectively.
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NKG2 (KLRC) (Human Gene Nomenclature Database (http://www.gene.ucl.ac.uk/ nomenclature) approves the following symbols: KLRC1 (NKG2-A), KLRC2 (NKG2-C), KLRC3 (NKG2-E), KLRC4 (NKG2-F), KLRD1 (CD94) and D12S2469E (NKG2-D)) and CD94 (KLRD1) genes are encoded on human chromosome 12p12-13, [14] [15] [16] which has been shown to be one of the candidate susceptibility regions of rheumatic diseases. 17, 18 Human chromosome 12p12-13 encodes many C-type lectin proteins preferentially expressed in NK cells, and is called 'the natural killer complex (NKC)'. 15, 16, 19 In the human NKC, five loci coding for NKG2 molecules NKG2-A (KLRC1), -C (KLRC2), -D (D12S2469E), -E (KLRC3) and NKG2-F (KLRC4) are present. NKG2-A, -C, -E and NKG2-F share substantial sequence homology, while NKG2-D is distantly related to the other NKG2 family members. [20] [21] [22] In contrast to killer cell Ig-like receptor (KIR) genes, where the number of loci possessed by an individual is variable because of the structural polymorphism of the leukocyte receptor complex (LRC) on chromosome 19q13, gross structural polymorphism of the NKG2 gene family has not been known, and all individuals are assumed to possess all of the NKG2 genes. 23, 24 Although recent reports demonstrated polymorphisms of NKG2 and CD94 genes from the analysis of a relatively small number of healthy individuals, 23, 25 neither population-based variation screening, nor analysis on the association between the polymorphisms and rheumatic diseases, has been reported.
This study was aimed at screening for polymorphisms of NKG2-A, -C and CD94 genes, and at testing their association with the susceptibility to rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Unexpectedly, in the process of polymorphism screening, evidence for a structural polymorphism resulting in NKG2-C deletion was obtained.
Results

New variations in NKG2-A, NKG2-C and CD94 genes
To detect new variations in NKG2-A, NKG2-C and CD94, we performed a variation screening of the entire coding regions of these genes with PCR-single strand conformation polymorphism (SSCP) using genomic DNA from 10 patients with RA, 10 patients with SLE and 12 healthy individuals (New variations detected in this study have been submitted to the DDBJ/EMBL/GenBank databases and assigned the accession numbers AB073867, AB073868, AB073869, AB073870, AB073871, AB073872, AB073873 and AB073874.) We detected 11 nucleotide sequence variations in NKG2-A (Figure 1a ). Only one of them, c.238T4A (the designations of the variations are based on references (ref. 26 ; http:/ /www.dmd.nl/ mutnomen.html)), was located in the coding region and resulted in a nonsynonymous substitution, Cys80Ser, within the transmembrane domain of NKG2-A. The other 10 variations observed were located in introns or in untranslated regions (UTRs). Among them, c.284-67_-62delAAACTT had already been deposited in the JSNP database (http:/ /snp.ims.u-tokyo.ac.jp/). The other 10 variations had not previously been reported.
In NKG2-C, in addition to the two previously reported nonsynonymous substitutions, c.5G4A (Ser2Asn) and c.305C4T (Ser102Phe) (GenBank accession number AJ001684 and NM_002260, respectively), 23, 25 two new variations, c.287-29T4A and c.704_705GC4AA, were observed in the noncoding region (Figure 1b) .
Only one substitution, c.-134A4T, was detected in the 5 0 UTR of CD94. Variations were not detected in the coding region of CD94 (Figure 1c ).
Analysis of association of NKG2-A and CD94 variations with susceptibility to RA or SLE We subsequently examined the detected variation sites in NKG2-A and CD94 for possible association with RA or SLE. As summarized in Table 1 , statistically significant association was not observed between the detected variations and RA or SLE. Association was not observed with any of the clinical subsets of SLE defined by the age of onset (r20), presence or absence of lupus nephritis, central nervous system lupus, anti-dsDNA antibody and anti-Sm antibody (data not shown). However, of interest, the nonsynonymous substitution, c.238T4A (Cys80Ser) in NKG2-A, was detected only in three patients with RA, but in none of the patients with SLE or healthy individuals.
Detection of NKG2-C deficiency in the general population In the process of variation screening of NKG2-C, we found that some genomic DNA samples could not be amplified by PCR using two sets of primers specific to two different segments of NKG2-C (see Materials and methods). We postulated that the lack of amplification might be caused by homozygous deletion of NKG2-C in such individuals. Next we tried long PCR to amplify approximately 24 kb encompassing NKG2-C, 21, 27 by placing the primers at the 3 0 end of NKG2-A and 5 0 upstream region of NKG2-E, as shown in Figure 2a . Even though we used high-molecular-weight genomic DNA as templates, the expected 24 kb products were not amplified in any of the samples, because the size of the fragment was too large. Instead, PCR product of approximately 8 kb was detected in a proportion of samples (Figure 2b ). The 8 kb fragment was always observed in samples in which no amplification was obtained in the PCR to amplify NKG2-C-specific intragenic fragments (Figure 2c ). These observations strongly suggested that the genomic region of approximately 16 kd encompassing NKG2-C was homozygously deleted in such samples.
To confirm the deletion, we performed Southern blot analysis to detect structural polymorphism in NKG2 gene family region. Southern blot was done using three different restriction enzymes, EcoRI, BamHI and TaqI, with the probe for 3 0 region of NKG2-C. As shown in Figure 3a , all enzymes revealed different band patterns between the samples with or without putative NKG2-C deletion. The DNA samples with the putative deletion of NKG2-C lacked one of the bands in every preparation, indicating the structural difference in the NKG2 gene family region. The other two bands detected in each preparation were considered to derive from crosshybridization of the probe to NKG2-A and NKG2-E, caused by substantial sequence homology among these genes.
To further confirm the deletion of NKG2-C, we performed RT-PCR analysis. As shown in Figure 3b , NKG2-A, -E and CD94 transcripts were detected in all of the samples tested. However, NKG2-C transcripts were not detected in individuals with putative homozygous deletion of NKG2-C.
Lack of association of NKG2-C polymorphisms with RA and SLE Finally, we examined whether NKG2-C deficiency or nonsynonymous substitutions are associated with susceptibility to RA and SLE. Since heterozygous deletion was not distinguishable from the common type using the ordinary genomic DNA preparation, only the frequency of homozygous NKG2-C deletion was compared. To our surprise, 4.3% of healthy donors were homozygous for the deletion of NKG2-C (Table 2) . No significant association was observed between homozygous deletion and tested diseases.
We also tested possible associations of c.5G4A and c.305C4T in NKG2-C with RA and SLE. To distinguish homozygotes and hemizygotes (ie variant allele on one chromosome and deletion on the other) of the variant allele, high-quality genomic DNA samples suitable for the amplification of 8 kb in a long PCR shown in Figure  2b were required; however, such samples were not available for most of the sample. Therefore, in this study, only allele carrier frequencies were compared between the patients and controls. A statistically significant difference was not observed (Table 2) . Association with disease subset of SLE was not observed either (data not shown).
Discussion
The most remarkable finding in this study is that individuals lacking NKG2-C are commonly present in The percentages are shown in parentheses. Statistically significant difference between patients and healthy individuals was not detected in any of the polymorphisms.
the general population. Although our current genotyping system cannot detect heterozygous deficiency, under the assumption of Hardy-Weinberg equilibrium, the presence of 4.3% of homozygous deficiency indicates that the frequencies of the deficient allele and heterozygous individuals amount to as much as 20.7 and 32.9%, respectively. Our finding contrasts with earlier studies which suggested that human NKC is relatively conserved, whereas NKCs are structurally polymorphic in chimpanzee, rhesus monkey and mouse: some chimpanzees have two NKG2-C genes and others lack NKG2-C or NKG2-D, 23, 25 the presence of multiple alleles in NKG2-A and NKG2-C was described in rhesus monkey, 28 each strain of mice has been shown to have different numbers of Ly49 genes, 29 and DBA/2J mice have recently been shown to be deficient in CD94. 30 The discrepancy between this study and earlier studies with respect to human NKC diversity may possibly derive from the differences in the sample size and populations. Thus, in the previous studies, relatively limited numbers (68 and 11) of donors were examined, 23, 25 and it is not surprising that individuals with homozygous deficiency were not present in the donors. In addition, in the previous studies the donors were mainly Caucasians, and it is possible that the frequency of deletion is lower in the Caucasians than in the Japanese.
It has already been known that polymorphisms derived from the presence or absence of some loci at the genomic level are present in gene clusters such as HLA, KIR and FCGR. [31] [32] [33] [34] [35] Like these loci, NKG2 genes are highly homologous to one another, suggesting that the NKC was evolved through multiple duplication and unequal crossover events.
The functional consequence of NKG2-C deficiency is at this stage unclear. Activating NKG2-C and inhibitory NKG2-A are highly homologous in their extracellular domains, and both of them recognize HLA-E as a ligand. While the function of NKG2-A is to inhibit the cytotoxic activity of NK cells, the role of NKG2-C remains unclear. It has been suggested that NKG2-C and NKG2-A are 
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Human NKG2 variations and NKG2-C deletion K Hikami et al expressed in different subsets of NK cells. 29, 36, 37 In the absence of NKG2-A, NKG2-C may be able to transmit activation signals to kill target cells which lost expression of HLA-B or -C (thus eliminating the inhibitory signals through KIR), but not that of HLA-E.
Alternatively, it is possible that NKG2-C is in some sense pathogen specific. NKG2-C may detect decoy ligand that viruses produce for the purpose of inhibiting NK cells, or may recognize viral antigens in the context of HLA-E. 38 In the case of mouse, Ly49h, a C-type lectinlike receptor encoded in the mouse NKC, has been shown to recognize specifically murine cytomegalovirus (MCMV), and Ly49h deficiency causes susceptibility to MCMV. [39] [40] [41] Similarly, rmp1 locus, which is associated with susceptibility to ectromelia (mousepox) virus infection, is located in the mouse NKC. 42 No matter what the exact role of NKG2-C may be, our data indicating that a proportion of apparently healthy individuals lack NKG2-C suggest that either NKG2-C is not essential for survival and reproduction, and/or NKG2-C and NKG2-E have a redundant role in humans. More frequent occurrence of polymorphisms associated with nonsynonymous substitutions in NKG2-C as compared with NKG2-A may also support this idea. Although our present data do not support association of NKG2-C deletion with RA or SLE in humans, association with other conditions, especially with resistance to certain viral infections, needs to be investigated in the future.
We also detected a number of new polymorphisms in NKG2-A, and one in CD94. Among them, Cys80Ser in the transmembrane region of NKG2-A was found only in three patients with RA, but not in SLE or in healthy individuals. Although a statistically significant difference was not observed, it is possible that this rare variation might be contributing to the susceptibility in a small proportion of RA. Of interest, one of the three patients with this substitution had a sister who was also suffering from RA. Unfortunately, this sister was not available for the study. Functional consequence of this substitution within the transmembrane region requires further investigation. In general, the paucity of polymorphism in the coding regions of NKG2-A and CD94 agrees with previous studies. 23, 25 In conclusion, we detected a number of new polymorphisms in NKG2-A and CD94, and also evidence for the deletion of NKG2-C in a proportion of general Japanese population. Our present data indicated that NKG2-A, NKG2-C and CD94 are unlikely to be susceptibility genes to these diseases, although a role for NKG2-A Cys80Ser substitution in a small proportion of RA cannot be excluded. Relatively common occurrence of NKG2-C deletion in general Japanese population is a new finding of particular interest. Its significance in terms of susceptibility to viral infections and evolutionary pathway of NKC requires further investigation.
Patients and methods
Subjects
A total of 201 patients with RA (male 26, female 175, mean age 57.5 7 11.6), 123 with SLE (male 13, female 110, mean age 40.5 7 13.3) and 215 healthy individuals (male:female B1 : 1, age 20-60) were studied. RA and SLE were diagnosed according to the American College of Rheumatology criteria. 43, 44 Healthy individuals consisted of the researchers, laboratory workers and students. All individuals were unrelated Japanese living in Tokyo area, the central part of Japan. This area has been shown to be homogeneous with respect to genetic background, permitting the case-control approach employed in this study. 45 This study was reviewed and approved by the research ethics committee of the Graduate School of Medicine, The University of Tokyo.
Preparation of genomic DNA Genomic DNA for variation screening and genotyping was purified from the peripheral blood leukocytes using a QIAmp blood kit (Qiagen, Hilden, Germany). Highmolecular-weight genomic DNA for Southern blotting was isolated from peripheral blood using a PUREGENE DNA Isolation Kit (Gentra systems, Minneapolis, MN, USA).
Variation screening of NKG2-A, NKG2-C and CD94 genes
Variation screening was performed using PCR-SSCP analysis. 46 Genomic DNA from 12 healthy individuals, 10 RA patients and 10 SLE patients was used for screening. Each coding region of NKG2-A, NKG2-C and CD94 was amplified using the specific primer sets designed within flanking introns or UTRs, based on the nucleotide sequences AF023840 for NKG2-A, AJ001684 for NKG2-C, and AB010084, Y14287 and Y14288 for CD94. After the PCR reaction, 1 ml each of the PCR product was mixed with 7 ml of denaturing solution (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol FF). The mixtures were denatured at 961C for 5 min and immediately cooled on ice. One microliter of the mixtures was applied to polyacrylamide gel (acrylamide: bis ¼ 49 : 1). Electrophoresis was carried out in 0.5 Â TBE under a constant electric current of 20 mA/gel for 90 min, using a minigel electrophoresis apparatus with a constant temperature control system (ATTO, Tokyo, Japan). The electrophoresis was performed in eight conditions with four different buffer temperatures with or without the addition of 5% glycerol into gels. After electrophoresis, single-strand DNA fragments in the gel were visualized by silver staining (Daiichi Pure Chemicals, Tokyo, Japan). Percentages are shown in parentheses. Statistically significant difference was not observed.
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Direct sequencing
The nucleotide sequences of the samples showing different SSCP patterns were determined by direct sequencing. PCR products were purified using the cartridge filter Suprec-02 (Takara, Otsu, Japan) and both sense and antisense strands were directly sequenced using the same primers as those used for the SSCP analysis. Fluorescence-based automated cycle sequencing of PCR products was performed with an automated sequencer (Applied Biosystems, Foster City, CA, USA) using a dRhodamine Terminator Cycle SequencingReady Reaction Kit (Applied Biosystems), according to the manufacturer's instructions.
Genotyping
Genotyping of NKG2-A c.-169G4A, c.-31-4A4G, c.238T4A, c.284-67_-62delAAACTT, c.388-90A4G and c.1015C4T was done using the PCR-SSCP method. 46 Primers for genotyping are shown in Table 3 . PCR was carried out using commercially available reagents (GeneAmp and AmpliTaq Gold, Perkin-Elmer, Norwalk, CT, USA). After preheating for 10 min at 961C, 35 cycles of PCR reaction that consists of denaturation for 30 s at 961C, annealing for 30 s at the temperature shown in Table 3 , and extension for 30 s at 721C were performed using thermal cyclers. Subsequently, SSCP electrophoresis was carried out under the conditions shown in Table 3 . For NKG2-A c.1015C4T genotyping, 7.5% instead of 10% acrylamide gel was used and electrophoresis was carried out for 120 min instead of 90 min. For NKG2-A c.1077C4T, c.1146_1150delGATTT and NKG2-C c.5G4A and c.305G4T, nested PCR was employed to overcome extensive homology between Table 3 Primers and SSCP conditions of variation screening and genotyping
Variation
Sequence ( NKG2-A, NKG2-C and NKG2-E genes. The first PCR was carried out using a Takara LA Taq kit (Takara). The PCR conditions were initial denaturation at 961C for 10 min, followed by 35 (for NKG2-A) or 20 (for NKG2-C) cycles of denaturation at 961C for 30 s, annealing at the temperature shown in Table 3 for 30 s, and extension at 721C for 1 (for NKG2-A) or 3 (for NKG2-C) min. Subsequently, NKG2-A c.1077C4T was genotyped using SSCP, c.1146_1150delGATTT by PCRsimple sequence length polymorphism SSLP, while genotyping of NKG2-C c.305C4T was performed by PCR-fluorescence resonance energy transfer (FRET) method using LightCycler (Roche Diagnostics, Mannheim, Germany), according to the manufacturer's instructions. For the latter, first PCR products were used as templates, and second PCR amplification was performed using the reaction mixture containing 0.4 mM MgCl 2 , 10 mM primers and 4 mM of hybridization probes (5 0 -LCRed-ATTCGGGGAAGAATTGTT-phosphate-3 0 and 5 0 -GTACTAATATCAGAACATTGAAAA-TAAAAATGTACCTTTCTGCGTTCTTG-fluorescein-3 0 ) for 50 cycles of denaturation for 5 s at 951C, annealing for 10 s at 541C, and extension for 15 s at 721C. Genotypes were determined from the melting curve analysis.
CD94 c. -134A4T was genotyped by PCR-sequencespecific primer (SSP) ( Table 3) . NKG2-A c.591-86C4A, c.591-22T4A and c.591-9C4T, and NKG2-C c.287-29T4A and c.704_705GC4AA were not examined because of the difficulty in genotyping, and also because such polymorphisms within introns and 3 0 UTR were considered less likely to be associated with functional significance.
Detection of NKG2-C deletion
To detect NKG2-C deletion, PCR amplification was performed with two sets of intragenic primers: a previously described set placed within exon 5 and exon 6 (5 0 -TTTCTGGCCAGCATTTTACCT-3 0 and 5 0 -CTGATG-CACTGTAAACGCAAAT-3 0 , primers 3 and 4 in Figure  2 ), which amplifies 1.1 kb fragment, 23 and the primers used for the first PCR for c.5G4A genotyping listed in Table 3 .
In addition, a long PCR was also designed to amplify a segment of approximately 24 kb encompassing NKG2-C locus. The primers were placed within exon 7 of NKG2-A and the promoter region of NKG2-E (5 0 -GCATTTG-CAGTGCATCAGATAAATTG-3 0 and 5 0 -GGTTCCTTCT-CTAATCATGACTTACTGTCTG-3 0 , primers 1 and 2 in Figure 2 ). The PCR was performed using a Takara LA Taq kit (Takara). The PCR condition consisted of initial denaturation at 961C for 10 min, followed by 35 cycles of denaturation at 961C for 30 s, annealing at 681C for 8 min 30 s and extension at 721C for 10 min.
Southern blotting
Southern blots were prepared by alkaline transfer of DNAs. A total of 10 mg each of high-molecular-weight DNA was digested with EcoRI, BamHI or TaqI. Digestion was performed in 100 ml reaction mixtures containing 10 mg genomic DNA, 100 U of enzyme in the manufacturer's buffer at 371C for EcoRI and BamHI, or at 651C for TaqI, overnight. Digests were separated by electrophoresis on 0.8% agarose gels at 25 V for 15 h and blotted overnight onto Hybond-N+ membranes (Amersham Pharmacia Biotech, Buckinghamshire, UK). The probe for the NKG2-C was made by PCR using the primers 5 0 -AAAGAGGACCCTAGGTGGTTTAC-3 0 and 5 0 -CTGATGCACTGTAAACGCAAAT-3 0 (2053 bp), and was labeled using DIG-High Prime (Roche Diagnostics, Basel, Switzerland). This probe hybridizes with NKG2-C intron 4 through 3 0 UTR in exon 6. Hybridization and detection were performed according to the manufacturer's instructions of a DIG Nucleic Acid Detection Kit (Roche Diagnostics).
RNA extraction and reverse transcription (RT)-PCR Total cellular RNA was prepared from peripheral blood leukocytes using RNeasy Total RNA System (Qiagen). First-strand cDNA was synthesized from extracted RNA using oligo(dT) primer (Promega, Madison, WI, USA) and MMLV reverse transcriptase (Toyobo, Osaka, Japan) at 421C for 45 min. RT-PCR was performed as previously described, 23 except for NKG2-C. RT-PCR for NKG2-C was done using the primers 5 0 -TTTCTGGCCAGCATTT-TACCT-3 0 and 5 0 -CTGATGCACTGTAAACGCAAAT-3 0 , because of the difficulty in amplification of NKG2-C using the primer set described in Ref. 23 .
Statistical analysis
The genotype frequency of the detected variations and the frequency of homozygous deletion of NKG2-C were compared between patients and healthy controls using w 2 test or Fisher's exact test. Fisher's exact test was used when one or more variables within 2 Â 2 tables were less than five. P-values o0.05 were regarded as statistically significant.
